Urea Cycle Disorders Treatment Market to be dominated by Increasing incidence of urea cycle disorders through 2027
Growing commonness of urea
cycle disorders and increasing research and development activities to drive the
urea cycle disorders treatment market in the forecast period, 2023-2027.
According to TechSci Research
report, “Urea Cycle Disorders Treatment Market - Global
Industry Size, Share, Trends, Opportunity, and Forecast, 2017-2027”, the global urea cycle disorders
treatment market is anticipated to grow at a significant rate in the forecast
period, 2023-2027. The increase in prevalence of urea cycle disorder, and
extensive research and development are the primary factors driving the growth
for the global urea cycle disorders treatment market. Growing expansion of infrastructure
development, and support from governments are expected to influence the market
demand. The increasing awareness among masses and growing number of innovative
diagnostic approaches are increasing the growth of the urea cycle disorders
treatment market, globally.
However, complications of long-term
therapy, production of these drugs, and challenges in diagnosing are likely to
hamper the growth of global urea cycle disorders treatment market.
Browse over XX market
data Figures spread through 110 Pages and an in-depth TOC on "Global Urea Cycle Disorders Treatment Market"
The global urea
cycle disorders treatment market is segmented into enzyme deficiency type,
treatment type, route of administration, distribution channel and company.
Based on enzyme
deficiency type, the market is divided into carbamyl phosphate synthetase
(CPS1), N-acetylglutamate synthetase (NAGS), ornithine transcarbamylase (OTC
deficiency), argininosuccinic acid synthetase (AS), argininosuccinate lyase (AL
or ASA lyase), and arginase (AG). The ornithine transcarbamylase (OTC
deficiency) segment is expected to witness the largest market share. This is
attributed to the rising product approvals and research and development
activities, globally.
Based on treatment type, the market is divided into amino acid
formulas, phenylbutyrate, sodium benzoate, and others. The sodium
benzoate segment is projected to grow at a significant rate over the forecast
period.
Based
on route of administration, the market is divided into oral and intravenous. The oral segment is
projected to spur the market growth as it is the most preferred method.
Based on distribution channel, the market is
divided into hospital pharmacies, retail pharmacies, and online pharmacies. The hospital
pharmacies segment is projected to grow at a significant rate over the forecast
period.
Major
operating companies operating in global urea cycle disorders treatment market are:
·
Bausch
Health Companies Inc.
·
Recordati
Rare Diseases
·
Eurocept
Pharmaceuticals Holding (Lucane Pharma SA)
·
Acer
Therapeutics
·
Ultragenyx
Pharmaceutical
·
Aeglea
BioTherapeutics
·
Arcturus
Therapeutics, Inc.
·
Orpharma
Pty Ltd.
·
Selecta
Biosciences, Inc
·
Abbott
Laboratories, Inc
Download Free Sample Report
Customers can
also request for 10% free customization on this report.
“North America dominates the
market in 2021 and is expected to maintain its dominance in the coming years
due to the increasing research and development by academic institutes in gene
therapy for the treatment of the urea cycle disorders. Also, owing
to the well-developed health care system, rising awareness among masses, association
of pharmaceutical and biotech companies with research institutes and acceptance
of the latest techniques in these nations are expected to propel the global urea
cycle disorders treatment market growth till 2027” said Mr. Karan Chechi,
Research Director with TechSci Research, a research based global management
consulting firm.
“Urea Cycle Disorders Treatment
Market - Global Industry Size, Share, Trends, Opportunity, and Forecast,
2017-2027 Segmented By Enzyme Deficiency Type (Carbamyl Phosphate
Synthetase (CPS1), N-Acetylglutamate Synthetase (NAGS), Ornithine
Transcarbamylase (OTC Deficiency), Argininosuccinic Acid Synthetase (AS),
Argininosuccinate Lyase (AL or ASA Lyase), Arginase (AG)), By Treatment Type
(Amino Acid Formulas, Phenylbutyrate, Sodium Benzoate, Others), By Route of
Administration (Oral v/s Intravenous), By Distribution Channel (Hospital
Pharmacies, Retail Pharmacies, Online Pharmacies), By Company, and By Region”, has evaluated the future
growth potential of global urea cycle disorders treatment and provides
statistics & information on market size, structure, and future market
growth. The report intends to provide cutting-edge market intelligence and help
decision makers take sound investment decisions. Besides, the report also
identifies and analyzes the emerging trends along with essential drivers,
challenges, and opportunities in global urea cycle disorders treatment market.
Contact
Mr. Ken Mathews
708 Third Avenue,
Manhattan, NY,
New York – 10017
Tel: +1-646-360-1656
Email: [email protected]
Website: https://www.techsciresearch.com